Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30893
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Denton, Christopher P | - |
dc.contributor.author | Goh, Nicole S L | - |
dc.contributor.author | Humphries, Stephen M | - |
dc.contributor.author | Maher, Toby M | - |
dc.contributor.author | Spiera, Robert | - |
dc.contributor.author | Devaraj, Anand | - |
dc.contributor.author | Ho, Lawrence | - |
dc.contributor.author | Stock, Christian | - |
dc.contributor.author | Erhardt, Elvira | - |
dc.contributor.author | Alves, Margarida | - |
dc.contributor.author | Wells, Athol U | - |
dc.date | 2022 | - |
dc.date.accessioned | 2022-09-20T06:51:49Z | - |
dc.date.available | 2022-09-20T06:51:49Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.citation | Rheumatology (Oxford, England) 2023-05-02; 62(5) | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/30893 | - |
dc.description.abstract | To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. We used generalised additive models, which involve few assumptions and allow for interaction between non-linear effects, to assess associations between the extent of fibrotic ILD on high-resolution computed tomography (HRCT), and the interplay of extent of fibrotic ILD on HRCT and FVC % predicted, at baseline and FVC decline over 52 weeks. In the placebo group (n = 288), there was weak evidence of a modest association between a greater extent of fibrotic ILD at baseline and a greater decline in FVC % predicted at week 52 (r: -0.09 [95% CI -0.2, 0.03]). Higher values of both the extent of fibrotic ILD and FVC % predicted at baseline tended to be associated with greater decline in FVC % predicted at week 52. In the nintedanib group (n = 288), there was no evidence of an association between the extent of fibrotic ILD at baseline and decline in FVC % predicted at week 52 (r: 0.01 [95% CI: -0.11, 0.12]) or between the interplay of extent of fibrotic ILD and FVC % predicted at baseline and decline in FVC % predicted at week 52. Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline. ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933. | en_US |
dc.language.iso | eng | - |
dc.subject | autoimmune diseases | en_US |
dc.subject | pulmonary fibrosis | en_US |
dc.subject | vital capacity | en_US |
dc.title | Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Rheumatology (Oxford, England) | en_US |
dc.identifier.affiliation | Center for Interstitial Lung Diseases, University of Washington, Seattle, Washington, USA | en_US |
dc.identifier.affiliation | Department of Radiology, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK | en_US |
dc.identifier.affiliation | National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK | en_US |
dc.identifier.affiliation | Department of Radiology, National Jewish Health, Denver, Colorado, USA | en_US |
dc.identifier.affiliation | National Heart and Lung Institute, Imperial College London, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA | en_US |
dc.identifier.affiliation | Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA | en_US |
dc.identifier.affiliation | Respiratory and Sleep Medicine | en_US |
dc.identifier.affiliation | Centre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, UK | en_US |
dc.identifier.affiliation | Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein. | en_US |
dc.identifier.affiliation | mainanalytics GmbH, Sulzbach, Germany. | en_US |
dc.identifier.affiliation | Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. | en_US |
dc.identifier.affiliation | Institute for Breathing and Sleep | en_US |
dc.identifier.doi | 10.1093/rheumatology/keac535 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 36111858 | - |
local.name.researcher | Goh, Nicole S L | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Respiratory and Sleep Medicine | - |
crisitem.author.dept | Institute for Breathing and Sleep | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.